A 2018 report estimates that mental health issues could cost the global economy $16 trillion between now and 2030. Psychedelic drugs are needed to mitigate those costs.
MagicMed Industries Files First Psychedelic Derivative Patent
MagicMed files with the USPTO with respect to its "broad portfolio of novel psilocybin molecular derivatives, the Psybrary™".
Stand and Deliver! Is The Great Big-Bank Bullion Robbery Finally Over?
Craig Hemke of TF Metals makes a powerful case that the days of the Big Banks bullying precious metals markets are coming to an end.
Pharmadrug Inc. Provides Update on Debt Restructuring
PharmaDrug is restructuring approximately $1 million in debt in the form of convertible debentures.
ATAI Life Sciences acquiring Kures to develop novel therapeutics for opioid abuse
Atai Life Sciences is bolstering its R&D platform with the acquisition of New York-based Kures.
Legalizing Medicinal Use of Psilocybin on Oregon’s November Ballot
Oregon could become the first U.S. state to LEGALIZE the (medicinal) use of a psychedelic drug.
Psychedelics Investing 101: Past and Current Psychedelic Drug Clinical Studies
Psychedelic drug R&D is ramping up rapidly. The number of past and current clinical studies on these substances will surprise you.
Epic Rally in Gold Mining Stocks Now Confirmed
The price of gold has just broken above $1,800 per ounce. Gold mining stocks were already in full rally mode. Get ready for take-off!
Osoyoos Provides Corporate Update on AI Pharma Acquisition
Osoyoos Cannabis provides additional details on its previously announced acquisition.
Psychedelics Investing 101: the Drug Approval Process and Drug Patents
Understanding the drug approval process that leads to drug patents and drug licensing is of critical importance for successful investing in psychedelics.
Mydecine Adds Biotech Heavy-Hitter To Science Team
Mydecine Innovations Group has added one of the world's pre-eminent biotech scientists to its Scientific Advisory Board.
IntelGenx and Cybin Corp Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film
Cybin Corp is partnering with IntelGenx Corp to produce a new delivery system for pharmaceutical-grade psilocybin.
